Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Sedation may be necessary in intensive care to facilitate diverse therapeutic interventions, but the use of sedative drugs may increase the risk of delirium and long-term cognitive impairment. Thus the implementation and monitoring of sedation remains difficult despite the use of sedation protocols and clinical sedation scores. Attempts to improve sedation monitoring through the use of the electroencephalogram(EEG) have been disappointing. Derived variables based on the unstimulated EEG fail to predict the response to external stimuli at the clinically most relevant light-to-moderate sedation levels, and the overlap between moderate and deep sedation levels is wide. We have demonstrated that long-latency auditory evoked potentials (ERPs)can be used to avoid deep levels of sedation in healthy volunteers during propofol sedation, independent of the concomitant administration of remifentanil. This approach has a potential clinical application for improved monitoring of sedation. Since the effects of different sedative drugs on the EEG may vary widely, the use of ERPs to monitor sedation needs to be evaluated with different sedative drugs. Therefore we will administer two widely used drug combinations (dexmedetomidine/remifentanil and midazolam/remifentanil) in healthy volunteers and record ERPS and processed EEG during clinical relevant sedation levels
| Condition | Intervention |
|---|---|
|
Conscious Sedation Deep Sedation Critical Care |
Drug: Dexmedetomidine Drug: Midazolam Drug: Remifentanil |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | The Effects of Dexmedetomidine/Remifentanil and Midazolam/Remifentanil on Auditory-evoked Potentials and Electroencephalogram at Light-to-moderate Sedation Levels in Healthy Subjects |
- Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus, Averaged Over 40 Stimuli)Awake and at 3 Different Drug-induced Sedation Levels [ Time Frame: awake + 3 sedation levels (RS2/3/4) (20 minutes each) ] [ Designated as safety issue: No ]Event Related Potentials (time-locked amplitudes in the electroencephalogram 100 milliseconds after the acoustic stimulus, averaged over 40 stimuli) Sedation levels were graded with the Ramsay scale (RS), where the responses of patients to standardized increasing stimuli (voice, then prodding, the pain stimulus) are graded. The higher the number, the deeper is the sedation. RS 6 means no response at all (= anesthesia)
- BIS-Index Awake and 3 Sedation Levels (RS 2/3/4) [ Time Frame: awake and 3 sedation levels (RS 2/3/4) 20 min each ] [ Designated as safety issue: No ]BIS-Index is a dimensionless value ranging from 0-100, indicating fully awake at 100 and a flat-line electroencephalogram at 0. Standard anesthesia creates a BIS-Index range 40-60. The scale is ordinal, not interval. BIS Index is calculated from the EEG by a proprietary algorithm (Aspect Medical Inc.)
| Enrollment: | 10 |
| Study Start Date: | March 2004 |
| Study Completion Date: | June 2004 |
| Primary Completion Date: | June 2004 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Dex/Remi followed by Mida/Remi
Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
|
Drug: Dexmedetomidine
Infusion of dexmedetomidine
Drug: Midazolam
Midazolam infusion
Drug: Remifentanil
Infusion of remifentanil
|
|
Active Comparator: Mida/Remi followed by Dexa/Remi
Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
|
Drug: Dexmedetomidine
Infusion of dexmedetomidine
Drug: Midazolam
Midazolam infusion
Drug: Remifentanil
Infusion of remifentanil
|
Detailed Description:
Sedation may be necessary in intensive care to facilitate diverse therapeutic interventions, but the use of sedative drugs may increase the risk of delirium and long-term cognitive impairment. Thus the implementation and monitoring of sedation remains difficult despite the use of sedation protocols and clinical sedation scores. Attempts to improve sedation monitoring through the use of the electroencephalogram (EEG) have been disappointing. Derived variables based on the unstimulated EEG fail to predict the response to external stimuli at the clinically most relevant light-to-moderate sedation levels, and the overlap between moderate and deep sedation levels is wide. We have demonstrated that long-latency auditory evoked potentials (ERPs)can be used to avoid deep levels of sedation in healthy volunteers during propofol sedation, independent of the concomitant administration of remifentanil. This approach has a potential clinical application for improved monitoring of sedation. Since the effects of different sedative drugs on the EEG may vary widely, the use of ERPs to monitor sedation needs to be evaluated with different sedative drugs. The alpha-2 agonist dexmedetomidine (dex) has been approved for short-term sedation in surgical intensive care unit (ICU) patients. Preliminary data suggest that the risk of delirium may be substantially reduced when dexmedetomidine is used to produce sedation. Since dexmedetomidine acts via different receptors and brain areas than do benzodiazepines and propofol, its impact on the brain electrophysiology may also be different. The assessment of dexmedetomidine's effects on the EEG and ERPs at various sedation levels has been limited in humans. We hypothesized that the combinations DEXMEDETOMIDINE/REMIFANTANIL (dex/remi) and MIDAZOLAM/REMIFENTANIL (mida/remi) would induce the same changes in EEG and long-latency ERPs during light-to-moderate levels of sedation in healthy subjects, despite the different quality of sedation that they provide. The opioid remifentanil was added because virtually all patients in the ICU have some level of pain and receive an opioid analgesic in combination with a sedative. 10 healthy subjects were assessed with both drug combinations (dex/remi and mida/remi), at least 7 days apart. The sequence of the drug combinations were randomized.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age 18 years and older
- healthy
Exclusion Criteria:
- History of problems during anesthesia
- Impairment of the auditory system
Contacts and Locations| Switzerland | |
| Departement of Intensive Care Medicine - University Hospital Bern - Inselspital | |
| Bern, Switzerland, 3010 | |
| Principal Investigator: | Matthias Haenggi, MD | University of Bern |
More Information
Publications:
| Responsible Party: | Matthias Haenggi, Department of Intensive Care Medicine, university Hospital Bern - Inselspital |
| ClinicalTrials.gov Identifier: | NCT00641563 History of Changes |
| Other Study ID Numbers: | KIM-NMP3 |
| Study First Received: | February 25, 2008 |
| Results First Received: | April 27, 2009 |
| Last Updated: | October 13, 2011 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by University Hospital Inselspital, Berne:
|
dexmedetomidine midazolam remifentanil Electroencephalography Event related potentials |
BIS Bispectral Index Response Entropy State Entropy |
Additional relevant MeSH terms:
|
Midazolam Dexmedetomidine Remifentanil Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs Hypnotics and Sedatives Anesthetics, Intravenous Anesthetics, General |
Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Analgesics, Opioid |
ClinicalTrials.gov processed this record on May 23, 2013